{"hands_on_practices": [{"introduction": "The number of receptors on a cell surface is not static; it is dynamically regulated, in part by epigenetic mechanisms. This exercise guides you through deriving and applying a cornerstone of quantitative pharmacology to predict how changes in receptor density ($B_{\\text{max}}$) alter a drug's potency, measured by its half-maximal effective concentration ($\\text{EC}_{50}$). Mastering this model is a core skill for understanding how variability in target gene expression, driven by epigenetics, can lead to different responses to the same drug dose [@problem_id:4948052].", "problem": "A partial agonist drug binds a receptor whose expression is modulated by epigenetic mechanisms such as histone acetylation and DNA methylation. Assume the law of mass action governs binding, so the concentration of drug–receptor complex is given by $[DR] = B_{\\max}\\frac{[D]}{K_{A} + [D]}$, where $[D]$ is the free drug concentration, $B_{\\max}$ is the total receptor density, and $K_{A}$ is the equilibrium dissociation constant. The cellular stimulus is proportional to the number of occupied receptors, $S = e\\,[DR]$, where $e$ is the intrinsic efficacy per occupied receptor. The downstream transduction from stimulus to measured effect is described by a hyperbolic Hill-type transducer function, $E = E_{\\max}\\frac{S^{n}}{S^{n} + K_{E}^{n}}$, where $E_{\\max}$ is the system’s maximal effect, $n$ is the Hill coefficient capturing cooperativity in transduction, and $K_{E}$ is a transduction constant.\n\n1. Starting from these definitions and the law of mass action, derive a closed-form expression for the half-maximal effective concentration ($\\text{EC}_{50}$), defined here as the concentration $[D]$ that produces one-half of the observed maximal effect $E_{\\text{obs,max}} = \\lim_{[D]\\to\\infty}E([D])$. Express your result in terms of $K_{A}$, $n$, and the dimensionless transduction parameter $\\tau \\equiv \\frac{e\\,B_{\\max}}{K_{E}}$.\n\n2. An epigenetic modification increases receptor transcription, leading to a two-fold increase in receptor density, so $B_{\\max}$ is multiplied by a factor $r = 2.0$. Assume $K_{A}$, $e$, and $K_{E}$ are unchanged. Let the initial transduction parameter be $\\tau_{0} = 0.50$ and the Hill coefficient be $n = 2.00$. Take $K_{A} = 40.0\\,\\text{nM}$. Using your derived expression, compute the new $\\text{EC}_{50}$ after the epigenetic change. Round your numerical answer to four significant figures and express the concentration in nM.", "solution": "The problem statement is scientifically sound, self-contained, and well-posed, providing a rigorous exercise in pharmacodynamic modeling. We may, therefore, proceed with the derivation and calculation.\n\nThe analysis begins with the set of given equations:\n1.  The concentration of the drug-receptor complex, $[DR]$, as a function of the free drug concentration, $[D]$, is given by the law of mass action:\n    $$[DR] = B_{\\max}\\frac{[D]}{K_{A} + [D]}$$\n    where $B_{\\max}$ is the total receptor density and $K_{A}$ is the equilibrium dissociation constant.\n\n2.  The cellular stimulus, $S$, is proportional to the concentration of occupied receptors:\n    $$S = e\\,[DR]$$\n    where $e$ is the intrinsic efficacy.\n\n3.  The measured effect, $E$, is related to the stimulus, $S$, by a hyperbolic Hill-type transducer function:\n    $$E = E_{\\max}\\frac{S^{n}}{S^{n} + K_{E}^{n}}$$\n    where $E_{\\max}$ is the system's maximal possible effect, $n$ is the Hill coefficient, and $K_{E}$ is a transduction constant.\n\nAdditionally, the dimensionless transduction parameter $\\tau$ is defined as $\\tau \\equiv \\frac{e\\,B_{\\max}}{K_{E}}$.\n\n**Part 1: Derivation of the $\\text{EC}_{50}$ Expression**\n\nFirst, we express the stimulus $S$ as a function of drug concentration $[D]$ by substituting the expression for $[DR]$ into the equation for $S$:\n$$S([D]) = e \\left( B_{\\max}\\frac{[D]}{K_{A} + [D]} \\right) = e B_{\\max} \\frac{[D]}{K_{A} + [D]}$$\nTo simplify subsequent expressions, we can express the ratio $\\frac{S}{K_{E}}$ in terms of $\\tau$:\n$$\\frac{S}{K_{E}} = \\frac{e B_{\\max}}{K_{E}} \\frac{[D]}{K_{A} + [D]} = \\tau \\frac{[D]}{K_{A} + [D]}$$\nNow, we rewrite the effect equation by dividing the numerator and denominator by $K_{E}^{n}$:\n$$E([D]) = E_{\\max}\\frac{(S/K_{E})^{n}}{(S/K_{E})^{n} + 1}$$\nSubstituting the expression for $S/K_{E}$ yields the full relationship between $E$ and $[D]$:\n$$E([D]) = E_{\\max}\\frac{\\left(\\tau \\frac{[D]}{K_{A} + [D]}\\right)^{n}}{\\left(\\tau \\frac{[D]}{K_{A} + [D]}\\right)^{n} + 1}$$\nThe half-maximal effective concentration, $\\text{EC}_{50}$, is defined as the drug concentration $[D]$ that produces one-half of the observed maximal effect, $E_{\\text{obs,max}}$. We first determine $E_{\\text{obs,max}}$ by taking the limit of $E([D])$ as $[D] \\to \\infty$:\n$$E_{\\text{obs,max}} = \\lim_{[D]\\to\\infty} E([D])$$\nAs $[D] \\to \\infty$, the term $\\frac{[D]}{K_{A} + [D]} \\to 1$. Consequently, the term $\\frac{S}{K_{E}}$ approaches its maximum value, $\\tau$. Substituting this into the effect equation gives:\n$$E_{\\text{obs,max}} = E_{\\max}\\frac{\\tau^{n}}{\\tau^{n} + 1}$$\nThe condition for $\\text{EC}_{50}$ is $E(\\text{EC}_{50}) = \\frac{1}{2} E_{\\text{obs,max}}$. Substituting the expressions for $E([D])$ and $E_{\\text{obs,max}}$ gives:\n$$E_{\\max}\\frac{\\left(\\tau \\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}\\right)^{n}}{\\left(\\tau \\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}\\right)^{n} + 1} = \\frac{1}{2} E_{\\max}\\frac{\\tau^{n}}{\\tau^{n} + 1}$$\nThe $E_{\\max}$ terms on both sides cancel. Let $U = \\tau \\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}$. The equation becomes:\n$$\\frac{U^{n}}{U^{n} + 1} = \\frac{1}{2} \\frac{\\tau^{n}}{\\tau^{n} + 1}$$\nWe solve for $U^n$:\n$$2U^{n}(\\tau^{n} + 1) = \\tau^{n}(U^{n} + 1)$$\n$$2U^{n}\\tau^{n} + 2U^{n} = U^{n}\\tau^{n} + \\tau^{n}$$\n$$U^{n}\\tau^{n} + 2U^{n} = \\tau^{n}$$\n$$U^{n}(\\tau^{n} + 2) = \\tau^{n}$$\n$$U^{n} = \\frac{\\tau^{n}}{\\tau^{n} + 2}$$\nNow, we substitute back $U = \\tau \\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}$:\n$$\\left(\\tau \\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}\\right)^{n} = \\frac{\\tau^{n}}{\\tau^{n} + 2}$$\n$$\\tau^{n} \\left(\\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}\\right)^{n} = \\frac{\\tau^{n}}{\\tau^{n} + 2}$$\nAssuming $\\tau \\ne 0$ (otherwise no effect is produced), we can divide by $\\tau^{n}$:\n$$\\left(\\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}}\\right)^{n} = \\frac{1}{\\tau^{n} + 2}$$\nTo solve for $\\text{EC}_{50}$, we first take the $n$-th root of both sides:\n$$\\frac{\\text{EC}_{50}}{K_{A} + \\text{EC}_{50}} = \\left(\\frac{1}{\\tau^{n} + 2}\\right)^{1/n} = (\\tau^{n} + 2)^{-1/n}$$\nTo isolate $\\text{EC}_{50}$, it is convenient to invert the expression:\n$$\\frac{K_{A} + \\text{EC}_{50}}{\\text{EC}_{50}} = (\\tau^{n} + 2)^{1/n}$$\n$$\\frac{K_{A}}{\\text{EC}_{50}} + 1 = (\\tau^{n} + 2)^{1/n}$$\n$$\\frac{K_{A}}{\\text{EC}_{50}} = (\\tau^{n} + 2)^{1/n} - 1$$\nFinally, solving for $\\text{EC}_{50}$, we arrive at the closed-form expression:\n$$\\text{EC}_{50} = \\frac{K_{A}}{(\\tau^{n} + 2)^{1/n} - 1}$$\n\n**Part 2: Calculation of the New $\\text{EC}_{50}$**\n\nWe are given the initial parameters: $\\tau_{0} = 0.50$, $n = 2.00$, and $K_{A} = 40.0\\,\\text{nM}$. An epigenetic modification leads to a two-fold increase in receptor density, so $B_{\\max}$ is multiplied by a factor $r = 2.0$. The parameters $K_{A}$, $e$, and $K_{E}$ are unchanged.\n\nThe new transduction parameter, $\\tau_{1}$, is related to the initial parameter, $\\tau_{0}$, as follows:\n$$\\tau_{1} = \\frac{e B_{\\text{max, new}}}{K_{E}} = \\frac{e (r \\cdot B_{\\text{max, old}})}{K_{E}} = r \\left(\\frac{e B_{\\text{max, old}}}{K_{E}}\\right) = r \\cdot \\tau_{0}$$\nSubstituting the given values:\n$$\\tau_{1} = 2.0 \\times 0.50 = 1.00$$\nWe now compute the new $\\text{EC}_{50}$, denoted $\\text{EC}_{50,1}$, using the expression derived in Part 1 with the new parameter $\\tau_{1}$ and the unchanged parameters $K_{A}$ and $n$:\n$$\\text{EC}_{50,1} = \\frac{K_{A}}{(\\tau_{1}^{n} + 2)^{1/n} - 1}$$\nSubstituting the numerical values $K_{A} = 40.0\\,\\text{nM}$, $\\tau_{1} = 1.00$, and $n = 2.00$:\n$$\\text{EC}_{50,1} = \\frac{40.0}{(1.00^{2.00} + 2)^{1/2.00} - 1} = \\frac{40.0}{(1 + 2)^{1/2} - 1} = \\frac{40.0}{\\sqrt{3} - 1}$$\nUsing the value $\\sqrt{3} \\approx 1.7320508$:\n$$\\text{EC}_{50,1} = \\frac{40.0}{1.7320508 - 1} = \\frac{40.0}{0.7320508} \\approx 54.641016\\,\\text{nM}$$\nRounding the result to four significant figures as requested, we obtain:\n$$\\text{EC}_{50,1} \\approx 54.64\\,\\text{nM}$$", "answer": "$$\\boxed{54.64}$$", "id": "4948052"}, {"introduction": "After exploring how target density can alter drug potency, we must think critically about how we measure drug efficacy. This practice presents a scenario where an epigenetic modification reduces the amount of an enzyme, a common type of drug target. Your task is to determine the impact of this change on the drug's *fractional inhibition* [@problem_id:4948057], a normalized measure of effect. The result reveals a subtle but fundamental principle of competitive enzyme inhibition and underscores the importance of choosing appropriate metrics in pharmacological studies.", "problem": "A cell line exhibits increased histone H3 lysine 27 trimethylation (H3K27me3) at the promoter of Epidermal Growth Factor Receptor (EGFR), resulting in a reduction of EGFR protein amount by a factor of $0.5$. EGFR functions as a kinase that catalyzes phosphorylation of a substrate with concentration $[S]$, and the catalytic rate obeys Michaelis–Menten kinetics under steady-state conditions. A small-molecule inhibitor $I$ is administered at a fixed dose and acts as a purely competitive inhibitor of the EGFR catalytic site. Assume the following are constant across conditions: the substrate concentration $[S] = 50\\,\\mathrm{nM}$, the Michaelis constant $K_m = 10\\,\\mathrm{nM}$, the inhibition constant $K_i = 20\\,\\mathrm{nM}$, and the inhibitor concentration $[I] = 100\\,\\mathrm{nM}$. Also assume the catalytic turnover number $k_{\\text{cat}}$ and $K_m$ are unaffected by the epigenetic change, and that total enzyme concentration scales with EGFR protein amount.\n\nDefine the inhibitor response at dose $[I]$ as the fractional inhibition of phosphorylation rate relative to the uninhibited baseline at the same substrate concentration, that is, the quantity $R$ given by the reduction in rate normalized to the baseline rate. Using only fundamental definitions of Michaelis–Menten kinetics and competitive inhibition, compute the expected change in the fractional inhibition $R$ at the fixed inhibitor dose due to the $0.5$ reduction in EGFR protein amount. Express your final answer as a single decimal number without units. No rounding is required.", "solution": "The problem requires the computation of the change in fractional inhibition, denoted as $R$, of an enzyme-catalyzed reaction due to an epigenetic event that reduces the total enzyme concentration. We must first validate the problem statement.\n\n### Step 1: Extract Givens\n- The epigenetic modification (histone H3 lysine 27 trimethylation, H3K27me3) reduces the amount of Epidermal Growth Factor Receptor (EGFR) protein by a factor of $0.5$.\n- The substrate concentration is constant: $[S] = 50\\,\\mathrm{nM}$.\n- The Michaelis constant is constant: $K_m = 10\\,\\mathrm{nM}$.\n- The inhibition constant for a competitive inhibitor $I$ is constant: $K_i = 20\\,\\mathrm{nM}$.\n- The inhibitor concentration is fixed: $[I] = 100\\,\\mathrm{nM}$.\n- The catalytic turnover number $k_{\\text{cat}}$ is constant.\n- Total enzyme concentration $[E]_{\\text{total}}$ is proportional to the EGFR protein amount.\n- The inhibitor $I$ is a purely competitive inhibitor.\n- The reaction follows Michaelis–Menten kinetics.\n- The fractional inhibition $R$ is defined as the reduction in rate normalized to the baseline (uninhibited) rate: $R = \\frac{v_0 - v_i}{v_0}$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, using established principles from molecular biology (H3K27me3 as a repressive mark), biochemistry (Michaelis-Menten kinetics), and pharmacology (competitive inhibition). The provided constants and concentrations are biochemically plausible. The problem is well-posed, as all necessary parameters and definitions are provided to determine a unique solution. The language is objective and precise. The crucial part of the validation is to assess if the problem is non-trivial or pseudo-profound. This requires examining the definition of fractional inhibition $R$. As will be shown in the solution, the fractional inhibition for a competitive inhibitor is independent of the total enzyme concentration. The problem is therefore a conceptual test of this principle, where an epigenetic event changes a parameter ($[E]_{\\text{total}}$) that turns out to be irrelevant to the final quantity of interest ($R$). This is a valid and insightful problem structure, not a flawed one.\n\n### Step 3: Verdict and Action\nThe problem is valid. The solution will proceed by deriving the expression for fractional inhibition and analyzing its dependence on the given parameters.\n\n### Solution Derivation\nThe objective is to calculate the change in fractional inhibition, $\\Delta R$, resulting from a change in the total enzyme concentration. Let the initial state be Condition 1, with total enzyme concentration $[E]_1$, and the final state after the epigenetic modification be Condition 2, with total enzyme concentration $[E]_2 = 0.5 [E]_1$. The change is $\\Delta R = R_2 - R_1$, where $R_1$ and $R_2$ are the fractional inhibitions in the respective conditions.\n\nThe fractional inhibition $R$ is defined as:\n$$R = \\frac{v_0 - v_i}{v_0} = 1 - \\frac{v_i}{v_0}$$\nwhere $v_0$ is the uninhibited reaction rate and $v_i$ is the inhibited rate.\n\nAccording to the Michaelis-Menten model, the uninhibited rate $v_0$ is given by:\n$$v_0 = \\frac{V_{\\max} [S]}{K_m + [S]}$$\nHere, $V_{\\max}$ is the maximum reaction rate, which is directly proportional to the total enzyme concentration $[E]_{\\text{total}}$ via the catalytic turnover number $k_{\\text{cat}}$: $V_{\\max} = k_{\\text{cat}} [E]_{\\text{total}}$. Thus:\n$$v_0 = \\frac{k_{\\text{cat}} [E]_{\\text{total}} [S]}{K_m + [S]}$$\n\nFor a purely competitive inhibitor, the inhibitor $I$ binds reversibly to the free enzyme, but not to the enzyme-substrate complex. This increases the apparent Michaelis constant to $K_{m, \\text{app}}$ without affecting $V_{\\max}$. The apparent Michaelis constant is given by:\n$$K_{m, \\text{app}} = K_m \\left(1 + \\frac{[I]}{K_i}\\right)$$\nThe rate of reaction in the presence of the competitive inhibitor, $v_i$, is therefore:\n$$v_i = \\frac{V_{\\max} [S]}{K_{m, \\text{app}} + [S]} = \\frac{V_{\\max} [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}$$\nSubstituting $V_{\\max} = k_{\\text{cat}} [E]_{\\text{total}}$, we have:\n$$v_i = \\frac{k_{\\text{cat}} [E]_{\\text{total}} [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}$$\n\nNow, let us substitute the expressions for $v_0$ and $v_i$ into the definition of fractional inhibition $R$:\n$$R = 1 - \\frac{v_i}{v_0} = 1 - \\frac{\\frac{k_{\\text{cat}} [E]_{\\text{total}} [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}}{\\frac{k_{\\text{cat}} [E]_{\\text{total}} [S]}{K_m + [S]}}$$\nThe term $k_{\\text{cat}} [E]_{\\text{total}} [S]$ is present in the numerator of both the top and bottom fractions, and since it is non-zero, it can be cancelled:\n$$R = 1 - \\frac{1 / \\left( K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S] \\right)}{1 / (K_m + [S])}$$\nSimplifying the complex fraction gives:\n$$R = 1 - \\frac{K_m + [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}$$\n\nThis final expression for $R$ depends only on the constants $K_m$, $K_i$, and the concentrations $[S]$ and $[I]$. Crucially, the expression for $R$ is independent of the total enzyme concentration, $[E]_{\\text{total}}$, and the catalytic turnover number, $k_{\\text{cat}}$.\n\nThe problem states that the epigenetic modification causes a change in the EGFR protein amount, which in turn changes the total enzyme concentration $[E]_{\\text{total}}$. Specifically, $[E]_2 = 0.5 [E]_1$. All other parameters in the expression for $R$ ($[S]$, $K_m$, $K_i$, $[I]$) are stated to be constant.\n\nSince the fractional inhibition $R$ is functionally independent of $[E]_{\\text{total}}$, the value of $R$ will be identical in both Condition 1 and Condition 2.\nLet $R_1$ be the fractional inhibition with enzyme concentration $[E]_1$, and $R_2$ be the fractional inhibition with enzyme concentration $[E]_2$.\n$$R_1 = 1 - \\frac{K_m + [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}$$\n$$R_2 = 1 - \\frac{K_m + [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}$$\nTherefore, $R_1 = R_2$.\n\nThe question asks for the change in the fractional inhibition, which is $\\Delta R = R_2 - R_1$.\n$$\\Delta R = R_2 - R_1 = 0$$\nThe numerical values provided for the constants ($[S] = 50\\,\\mathrm{nM}$, $K_m = 10\\,\\mathrm{nM}$, $K_i = 20\\,\\mathrm{nM}$, $[I] = 100\\,\\mathrm{nM}$) are not required to determine the change in $R$, as the change is fundamentally zero based on the definition of fractional inhibition for a competitive inhibitor. The absolute rates $v_0$ and $v_i$ would both decrease by a factor of $0.5$, but their ratio $v_i/v_0$ and thus the fractional inhibition $R$ remain constant.\nThe final answer is $0$.", "answer": "$$\\boxed{0}$$", "id": "4948057"}, {"introduction": "A drug's success depends not only on its interaction with the target but also on its ability to reach and remain at that target. This final practice models how epigenetic upregulation of a drug efflux pump, a classic mechanism of multidrug resistance, affects the intracellular drug concentration. By applying a simple mass-balance model [@problem_id:4948043], you will quantify how an epigenetic change that increases the expression of a transporter like ABCB1 can directly counteract a drug's therapeutic goal by actively removing it from the cell.", "problem": "A small-molecule anticancer drug is administered to cells in culture. The extracellular concentration is clamped at a constant value $C_{e}$ by the medium. The drug enters the cell predominantly by permeability-limited passive diffusion across the plasma membrane, which at the cellular scale can be approximated as a linear flux proportional to the transmembrane concentration difference, $J_{\\text{in}} = k_{\\text{in}}(C_{e} - C_{i})$, where $k_{\\text{in}}$ is a lumped influx rate coefficient and $C_{i}$ is the intracellular concentration. The drug is removed from the cell by efflux mediated by ATP-Binding Cassette Subfamily B Member 1 (ABCB1, also known as P-glycoprotein), which under low substrate conditions can be approximated as first-order in $C_{i}$, $J_{\\text{eff}} = k_{\\text{eff}} C_{i}$, where $k_{\\text{eff}}$ is a lumped efflux rate coefficient proportional to transporter abundance.\n\nTargeted demethylation of the Deoxyribonucleic Acid (DNA) promoter region of the ABCB1 gene doubles transporter expression, and under the linear regime this is taken to double $k_{\\text{eff}}$ (that is, $k_{\\text{eff}} \\to 2 k_{\\text{eff}}$), without changing $k_{\\text{in}}$ or $C_{e}$.\n\nAssuming a single-compartment mass balance and steady state ($dC_{i}/dt = 0$) both before and after demethylation, derive the closed-form expression for the multiplicative change in steady-state intracellular concentration due to demethylation, defined as $R = \\dfrac{C_{i,\\text{post}}}{C_{i,\\text{pre}}}$, in terms of $k_{\\text{in}}$ and $k_{\\text{eff}}$. Express your final answer as a single simplified analytic expression. No rounding is required. Report the dimensionless factor $R$ (no units).", "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of pharmacokinetics and cell biology, employing a standard single-compartment model with passive influx and first-order efflux. The problem is well-posed, providing all necessary definitions, constants, and conditions ($J_{\\text{in}} = k_{\\text{in}}(C_{e} - C_{i})$, $J_{\\text{eff}} = k_{\\text{eff}} C_{i}$, steady-state condition $dC_{i}/dt = 0$, and the specific perturbation $k_{\\text{eff}} \\to 2 k_{\\text{eff}}$) to derive a unique, meaningful solution for the requested ratio $R$. The language is objective and the setup is internally consistent.\n\nThe rate of change of the intracellular drug concentration, $C_{i}$, is modeled by a first-order ordinary differential equation representing the mass balance of drug influx and efflux. The governing equation is:\n$$\n\\frac{dC_{i}}{dt} = J_{\\text{in}} - J_{\\text{eff}}\n$$\nSubstituting the provided expressions for the influx flux, $J_{\\text{in}}$, and the efflux flux, $J_{\\text{eff}}$:\n$$\n\\frac{dC_{i}}{dt} = k_{\\text{in}}(C_{e} - C_{i}) - k_{\\text{eff}} C_{i}\n$$\nHere, $k_{\\text{in}}$ is the influx rate coefficient, $k_{\\text{eff}}$ is the efflux rate coefficient, $C_{e}$ is the constant extracellular concentration, and $C_{i}$ is the intracellular concentration.\n\nThe problem requires a solution at steady state, which is defined by the condition that the intracellular concentration is no longer changing with time. Mathematically, this corresponds to setting the time derivative to zero:\n$$\n\\frac{dC_{i}}{dt} = 0\n$$\nApplying this condition to the governing equation, we obtain an algebraic equation for the steady-state intracellular concentration, which we denote as $C_{i,ss}$:\n$$\n0 = k_{\\text{in}}(C_{e} - C_{i,ss}) - k_{\\text{eff}} C_{i,ss}\n$$\nWe can now solve for $C_{i,ss}$ in terms of the system parameters:\n$$\nk_{\\text{in}} C_{e} - k_{\\text{in}} C_{i,ss} - k_{\\text{eff}} C_{i,ss} = 0\n$$\n$$\nk_{\\text{in}} C_{e} = (k_{\\text{in}} + k_{\\text{eff}}) C_{i,ss}\n$$\n$$\nC_{i,ss} = \\frac{k_{\\text{in}}}{k_{\\text{in}} + k_{\\text{eff}}} C_{e}\n$$\nThis equation represents the general solution for the steady-state intracellular concentration.\n\nWe next apply this general solution to the two scenarios described in the problem: before (pre) and after (post) the demethylation event.\n\nBefore demethylation, the system is characterized by the rate coefficients $k_{\\text{in}}$ and $k_{\\text{eff}}$. The steady-state concentration, $C_{i,\\text{pre}}$, is therefore:\n$$\nC_{i,\\text{pre}} = \\frac{k_{\\text{in}}}{k_{\\text{in}} + k_{\\text{eff}}} C_{e}\n$$\nAfter demethylation, the problem states that the expression of the ABCB1 transporter is doubled, which results in a doubling of the efflux rate coefficient, such that the new coefficient is $2 k_{\\text{eff}}$. The parameters $k_{\\text{in}}$ and $C_{e}$ are unaffected. The new steady-state concentration, $C_{i,\\text{post}}$, is found by substituting $2 k_{\\text{eff}}$ in place of $k_{\\text{eff}}$ in the general steady-state formula:\n$$\nC_{i,\\text{post}} = \\frac{k_{\\text{in}}}{k_{\\text{in}} + 2 k_{\\text{eff}}} C_{e}\n$$\nThe problem asks for the multiplicative change, defined as the ratio $R = \\dfrac{C_{i,\\text{post}}}{C_{i,\\text{pre}}}$. We compute this ratio using the expressions derived above:\n$$\nR = \\frac{C_{i,\\text{post}}}{C_{i,\\text{pre}}} = \\frac{\\frac{k_{\\text{in}}}{k_{\\text{in}} + 2 k_{\\text{eff}}} C_{e}}{\\frac{k_{\\text{in}}}{k_{\\text{in}} + k_{\\text{eff}}} C_{e}}\n$$\nThe terms $k_{\\text{in}}$ and $C_{e}$ are common to both the numerator and the denominator, so they cancel out:\n$$\nR = \\frac{\\frac{1}{k_{\\text{in}} + 2 k_{\\text{eff}}}}{\\frac{1}{k_{\\text{in}} + k_{\\text{eff}}}}\n$$\nSimplifying this complex fraction gives the final expression for $R$:\n$$\nR = \\frac{k_{\\text{in}} + k_{\\text{eff}}}{k_{\\text{in}} + 2 k_{\\text{eff}}}\n$$\nThis result is a dimensionless analytical expression in terms of the rate coefficients $k_{\\text{in}}$ and $k_{\\text{eff}}$, as required.", "answer": "$$\n\\boxed{\\frac{k_{\\text{in}} + k_{\\text{eff}}}{k_{\\text{in}} + 2 k_{\\text{eff}}}}\n$$", "id": "4948043"}]}